Clinical Trial Search

Primary: AUC 0-infinity (Area Under the Concentration-time Curve of the Cyclo in Plasma Over the Time Interval From 0 Extrapolated to Infinity) — 672; 732 ng*h/mL — p=0.0033

Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs

Primary: Number of Drinking Days — 17.6; 12.6 days — p=0.014

Primary: Transfusion Requirement — 1.6; 2.2 units

Primary: Maximum Tolerated Dose of Temsirolimus — 115 mg/week

Primary: Objective Response Rate (ORR) — 14.3 Percentage of participants

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I — 3; 8; 4; 9 Participants

Primary: Drinks Per Drinking Day — 7.2; 7.8; 5.2 drinks per drinking day — p=0.49

Primary: Major Mobility Disability, Defined as Incapacity to Walk 400 Meters — 246; 290 participants — p=0.03

Primary: Direct Evaluation of the Sirtuin 1 Gene Expression — 11.04; 11.43; 12.84; 12.05 arbitrary unit relative to control gene

Primary: Visual Acuity - Hema-copolymer and Etafilcon A — -0.08; -0.04; 0.17; 0.20 logMAR

Primary: Radlex Scale for Diagnostic Capability Ratings — 3.0388; 3.0547 units on a scale — p=0.028

Primary: HCV RNA Profile During The First 24 Weeks — 6.50; 6.61; 6.55; 6.53 log 10 copies/mL

Primary: HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment — -0.56; -0.65; 0.14 Percentage of HbA1c — p=<0.0001